Published in Infect Immun on December 01, 2000
Toxoplasma gondii effectors are master regulators of the inflammatory response. Trends Parasitol (2011) 1.53
Communication between Toxoplasma gondii and its host: impact on parasite growth, development, immune evasion, and virulence. APMIS (2009) 1.36
NK cells help to induce CD8(+)-T-cell immunity against Toxoplasma gondii in the absence of CD4(+) T cells. Infect Immun (2005) 1.23
Genetic approaches to studying virulence and pathogenesis in Toxoplasma gondii. Philos Trans R Soc Lond B Biol Sci (2002) 1.21
Innate responses to Toxoplasma gondii in mice and humans. Trends Parasitol (2011) 1.15
Dual role for inflammasome sensors NLRP1 and NLRP3 in murine resistance to Toxoplasma gondii. MBio (2014) 1.09
Transient transgenic expression of gamma interferon promotes Legionella pneumophila clearance in immunocompetent hosts. Infect Immun (2001) 1.07
Contribution of interleukin-12 (IL-12) and the CD28/B7 and CD40/CD40 ligand pathways to the development of a pathological T-cell response in IL-10-deficient mice. Infect Immun (2002) 1.01
Opposing roles of NF-kappaB family members in the regulation of NK cell proliferation and production of IFN-gamma. Int Immunol (2006) 1.01
Evidence of the involvement of caspase-1 under physiologic and pathologic cellular stress during human pregnancy: a link between the inflammasome and parturition. J Matern Fetal Neonatal Med (2008) 0.99
Toxoplasma gondii cyclophilin 18-mediated production of nitric oxide induces Bradyzoite conversion in a CCR5-dependent manner. Infect Immun (2009) 0.96
Early response of mucosal epithelial cells during Toxoplasma gondii infection. J Immunol (2009) 0.96
B7RP-1-ICOS interactions are required for optimal infection-induced expansion of CD4+ Th1 and Th2 responses. J Immunol (2006) 0.94
Interleukin-18 is an essential element in host resistance to experimental group B streptococcal disease in neonates. Infect Immun (2004) 0.92
A potential role for interleukin-18 in inhibition of the development of Cryptosporidium parvum. Clin Exp Immunol (2006) 0.90
Infection with Toxoplasma gondii increases atherosclerotic lesion in ApoE-deficient mice. Infect Immun (2004) 0.81
Transient overexpression of gamma interferon promotes Aspergillus clearance in invasive pulmonary aspergillosis. Clin Exp Immunol (2005) 0.81
Foxp4 is dispensable for T cell development, but required for robust recall responses. PLoS One (2012) 0.81
Vaccination with Toxoplasma lysate antigen and CpG oligodeoxynucleotides: comparison of immune responses in intranasal versus intramuscular administrations. Parasitol Res (2014) 0.78
Endogenous interleukin-18 is involved in immunity to Leishmania donovani but its absence does not adversely influence the therapeutic activity of sodium stibogluconate. Immunology (2006) 0.78
Altered endochondral ossification in collagen X mouse models leads to impaired immune responses. Dev Dyn (2008) 0.78
IL-18 gene polymorphism in patients with visceral leishmaniasis in East Azarbaijan, Iran. J Parasit Dis (2014) 0.75
Toxoplasma gondii Infection Induces High Mobility Group Box 1 Released from Mouse Macrophages. Front Microbiol (2017) 0.75
Biology of natural killer cells. Adv Immunol (1989) 14.77
Cloning of a new cytokine that induces IFN-gamma production by T cells. Nature (1995) 10.89
Interferon-gamma: the major mediator of resistance against Toxoplasma gondii. Science (1988) 7.96
Interleukin 12 is required for the T-lymphocyte-independent induction of interferon gamma by an intracellular parasite and induces resistance in T-cell-deficient hosts. Proc Natl Acad Sci U S A (1993) 6.87
Caspase-1 processes IFN-gamma-inducing factor and regulates LPS-induced IFN-gamma production. Nature (1997) 5.35
Activation of interferon-gamma inducing factor mediated by interleukin-1beta converting enzyme. Science (1997) 5.16
Defective NK cell activity and Th1 response in IL-18-deficient mice. Immunity (1998) 4.70
Impairment of mycobacterial immunity in human interleukin-12 receptor deficiency. Science (1998) 4.58
Severe mycobacterial and Salmonella infections in interleukin-12 receptor-deficient patients. Science (1998) 4.24
IL-12 up-regulates IL-18 receptor expression on T cells, Th1 cells, and B cells: synergism with IL-18 for IFN-gamma production. J Immunol (1998) 3.56
Importance of endogenous IFN-gamma for prevention of toxoplasmic encephalitis in mice. J Immunol (1989) 3.20
Differential cytokine and chemokine gene expression by human NK cells following activation with IL-18 or IL-15 in combination with IL-12: implications for the innate immune response. J Immunol (1999) 3.18
In the absence of endogenous IFN-gamma, mice develop unimpaired IL-12 responses to Toxoplasma gondii while failing to control acute infection. J Immunol (1996) 3.15
Murine macrophages secrete interferon gamma upon combined stimulation with interleukin (IL)-12 and IL-18: A novel pathway of autocrine macrophage activation. J Exp Med (1998) 2.89
IL-18, a novel immunoregulatory cytokine, is up-regulated in Crohn's disease: expression and localization in intestinal mucosal cells. J Immunol (1999) 2.58
Production of gamma interferon by natural killer cells from Toxoplasma gondii-infected SCID mice: regulation by interleukin-10, interleukin-12, and tumor necrosis factor alpha. Infect Immun (1994) 2.48
Bioactive IL-18 expression is up-regulated in Crohn's disease. J Immunol (1999) 2.38
Virus infection activates IL-1 beta and IL-18 production in human macrophages by a caspase-1-dependent pathway. J Immunol (1999) 2.26
Interleukin-18: a novel cytokine that augments both innate and acquired immunity. Adv Immunol (1998) 2.23
Induction of interferon-gamma production in Th1 CD4+ T cells: evidence for two distinct pathways for promoter activation. Eur J Immunol (1999) 2.14
Interleukin 18 contributes to host resistance and gamma interferon production in mice infected with virulent Salmonella typhimurium. Infect Immun (1999) 2.14
In vivo recombinant interleukin 2 administration enhances survival against a lethal challenge with Toxoplasma gondii. J Immunol (1985) 2.00
Interleukin-12 and interleukin-18 synergistically induce murine tumor regression which involves inhibition of angiogenesis. J Clin Invest (1998) 1.93
Interleukin 18 together with interleukin 12 inhibits IgE production by induction of interferon-gamma production from activated B cells. Proc Natl Acad Sci U S A (1997) 1.92
Role of interleukin-18 (IL-18) in mycobacterial infection in IL-18-gene-disrupted mice. Infect Immun (1999) 1.85
A protective role for endogenous tumor necrosis factor in Toxoplasma gondii infection. Infect Immun (1992) 1.79
IL-1 beta is required for IL-12 to induce production of IFN-gamma by NK cells. A role for IL-1 beta in the T cell-independent mechanism of resistance against intracellular pathogens. J Immunol (1995) 1.76
IL-18 (IFN-gamma-inducing factor) regulates early cytokine production in, and promotes resolution of, bacterial infection in mice. J Immunol (1998) 1.73
Interleukin-12 (IL-12) and IL-18 synergistically induce the fungicidal activity of murine peritoneal exudate cells against Cryptococcus neoformans through production of gamma interferon by natural killer cells. Infect Immun (1997) 1.71
A newly defined interleukin-1? Nature (1996) 1.64
Similar frequencies and kinetics of cytokine producing cells in murine peripheral blood and spleen. Cytokine detection by immunoassay and intracellular immunostaining. J Immunol Methods (1993) 1.60
Synergistic effects of IL-4 and IL-18 on IL-12-dependent IFN-gamma production by dendritic cells. J Immunol (2000) 1.56
IL-12 is not required for induction of type 1 cytokine responses in viral infections. J Immunol (1999) 1.50
IL-18 up-regulates perforin-mediated NK activity without increasing perforin messenger RNA expression by binding to constitutively expressed IL-18 receptor. J Immunol (1999) 1.48
IL-10 enhances NK cell proliferation, cytotoxicity and production of IFN-gamma when combined with IL-18. Eur J Immunol (1999) 1.45
Studies on the role of interleukin-12 in acute murine toxoplasmosis. Immunology (1995) 1.43
Nitric oxide prevents IL-1beta and IFN-gamma-inducing factor (IL-18) release from macrophages by inhibiting caspase-1 (IL-1beta-converting enzyme). J Immunol (1998) 1.42
Interleukin-18 activates NF-kappaB in murine T helper type 1 cells. Biochem Biophys Res Commun (1997) 1.37
A signal transducer and activator of transcription (Stat)4-independent pathway for the development of T helper type 1 cells. J Exp Med (1998) 1.36
IL-18 augments perforin-dependent cytotoxicity of liver NK-T cells. J Immunol (1998) 1.33
Altered immune responses and susceptibility to Leishmania major and Staphylococcus aureus infection in IL-18-deficient mice. J Immunol (1999) 1.32
Defective interleukin (IL)-18-mediated natural killer and T helper cell type 1 responses in IL-1 receptor-associated kinase (IRAK)-deficient mice. J Exp Med (1999) 1.30
Host resistance to Toxoplasma gondii: model for studying the selective induction of cell-mediated immunity by intracellular parasites. Infect Agents Dis (1993) 1.28
IFN-gamma-inducing factor/IL-18 administration mediates IFN-gamma- and IL-12-independent antitumor effects. J Immunol (1998) 1.28
Differential antitumor effects of administration of recombinant IL-18 or recombinant IL-12 are mediated primarily by Fas-Fas ligand- and perforin-induced tumor apoptosis, respectively. J Immunol (1999) 1.22
IL-18 and CD28 use distinct molecular mechanisms to enhance NK cell production of IL-12-induced IFN-gamma. J Immunol (1999) 1.20
Comparison of the effects of interleukin-1 alpha, interleukin-1 beta and interferon-gamma-inducing factor on the production of interferon-gamma by natural killer. Eur J Immunol (1997) 1.18
Interleukin-18/interferon-gamma-inducing factor, a novel cytokine, up-regulates ICAM-1 (CD54) expression in KG-1 cells. J Leukoc Biol (1998) 1.16
Binding of interleukin-18 to the interleukin-1 receptor homologous receptor IL-1Rrp1 leads to activation of signaling pathways similar to those used by interleukin-1. J Interferon Cytokine Res (1998) 1.15
Potentiality of interleukin-18 as a useful reagent for treatment and prevention of Leishmania major infection. Infect Immun (2000) 1.13
The role of the CD28/B7 interaction in the regulation of NK cell responses during infection with Toxoplasma gondii. J Immunol (1997) 1.12
Role of endogenous interleukin-18 in resolving wild-type and attenuated Salmonella typhimurium infections. Infect Immun (1999) 1.09
Augmentation of the CD8+ T cell response by IFN-gamma in IL-12-deficient mice during Toxoplasma gondii infection. J Immunol (1999) 1.09
Interleukin 18 induces the sequential activation of natural killer cells and cytotoxic T lymphocytes to protect syngeneic mice from transplantation with Meth A sarcoma. Cancer Res (1997) 1.05
Combined effects of IL-12 and IL-18 on the clinical course and local cytokine production in murine pulmonary infection with Cryptococcus neoformans. Eur J Immunol (1999) 0.94
Toxoplasma gondii: evidence for interleukin-12-dependent and-independent pathways of interferon-gamma production induced by an attenuated parasite strain. Exp Parasitol (1996) 0.93
Limited interleukin-18 response in Salmonella-infected murine macrophages and in Salmonella-infected mice. Infect Immun (1999) 0.89
Antitumor effects on mouse melanoma elicited by local secretion of interleukin-12 and their enhancement by treatment with interleukin-18. Cancer Invest (2000) 0.79
Interleukin 10 is a potent growth and differentiation factor for activated human B lymphocytes. Proc Natl Acad Sci U S A (1992) 6.37
Isolation and expression of human cytokine synthesis inhibitory factor cDNA clones: homology to Epstein-Barr virus open reading frame BCRFI. Proc Natl Acad Sci U S A (1991) 5.02
Interleukin 10, a novel B cell stimulatory factor: unresponsiveness of X chromosome-linked immunodeficiency B cells. J Exp Med (1990) 4.30
IGIF does not drive Th1 development but synergizes with IL-12 for interferon-gamma production and activates IRAK and NFkappaB. Immunity (1997) 3.60
Bystander activation of CD8+ T cells contributes to the rapid production of IFN-gamma in response to bacterial pathogens. J Immunol (2001) 2.70
Aluminium hydroxide adjuvant initiates strong antigen-specific Th2 responses in the absence of IL-4- or IL-13-mediated signaling. J Immunol (1999) 2.53
Sequence-dependent DNA structure: tetranucleotide conformational maps. J Mol Biol (2000) 2.13
Advances in understanding the anti-inflammatory properties of IL-27. Immunol Lett (2008) 2.04
IL-10 mediates susceptibility to Leishmania donovani infection. Eur J Immunol (2001) 1.99
Ligand for FLT3/FLK2 receptor tyrosine kinase regulates growth of haematopoietic stem cells and is encoded by variant RNAs. Nature (1994) 1.98
Interleukin-12 and interleukin-18 synergistically induce murine tumor regression which involves inhibition of angiogenesis. J Clin Invest (1998) 1.93
Sequence-dependent DNA structure: dinucleotide conformational maps. J Mol Biol (2000) 1.86
Regulation of tumor necrosis factor production by adrenaline and beta-adrenergic agonists. J Immunol (1992) 1.83
Definitive identification of a gene that confers resistance against Toxoplasma cyst burden and encephalitis. Immunology (1995) 1.76
Modulation of murine macrophage function by IL-13. J Immunol (1993) 1.66
Mitogen- and antigen-specific proliferation of T cells in murine toxoplasmosis is inhibited by reactive nitrogen intermediates. Infect Immun (1994) 1.66
Host-pathogen interactions: subversion and utilization of the NF-kappa B pathway during infection. Infect Immun (2002) 1.65
An Epidemic of Diarrhea in a New-Born Nursery Caused by Pseudomonas aeruginosa. Am J Public Health Nations Health (1947) 1.51
Inhibition of interferon gamma induced interleukin 12 production: a potential mechanism for the anti-inflammatory activities of tumor necrosis factor. Proc Natl Acad Sci U S A (1998) 1.50
Species-specificity of T cell stimulating activities of IL 2 and BSF-1 (IL 4): comparison of normal and recombinant, mouse and human IL 2 and BSF-1 (IL 4). J Immunol (1987) 1.48
gp130 at the nexus of inflammation, autoimmunity, and cancer. J Leukoc Biol (2010) 1.48
T cell activation-inducing epitopes of the house dust mite allergen Der p I. Proliferation and lymphokine production patterns by Der p I-specific CD4+ T cell clones. J Immunol (1992) 1.46
IL-10 enhances NK cell proliferation, cytotoxicity and production of IFN-gamma when combined with IL-18. Eur J Immunol (1999) 1.45
Role of interleukin-10 in regulation of T-cell-dependent and T-cell-independent mechanisms of resistance to Toxoplasma gondii. Infect Immun (1997) 1.44
IL-4 inhibits IL-2-mediated induction of human lymphokine-activated killer cells, but not the generation of antigen-specific cytotoxic T lymphocytes in mixed leukocyte cultures. J Immunol (1988) 1.38
IL-1 alpha and TNF-alpha are required for IL-12-induced development of Th1 cells producing high levels of IFN-gamma in BALB/c but not C57BL/6 mice. J Immunol (1998) 1.38
Structure and conformation of helical nucleic acids: analysis program (SCHNAaP). J Mol Biol (1997) 1.36
The CD40/CD40 ligand interaction is required for resistance to toxoplasmic encephalitis. Infect Immun (2000) 1.31
Suppression of NF-kappaB activation by infection with Toxoplasma gondii. J Infect Dis (2002) 1.24
The NF-kappa B family member RelB is required for innate and adaptive immunity to Toxoplasma gondii. J Immunol (1999) 1.22
IL-18 and CD28 use distinct molecular mechanisms to enhance NK cell production of IL-12-induced IFN-gamma. J Immunol (1999) 1.20
A DNA damage and stress inducible G protein-coupled receptor blocks cells in G2/M. Proc Natl Acad Sci U S A (1998) 1.18
Cytokine networking in lungs of immunocompetent mice in response to inhaled Aspergillus fumigatus. Infect Immun (2001) 1.17
The CD28/B7 interaction is not required for resistance to Toxoplasma gondii in the brain but contributes to the development of immunopathology. J Immunol (1999) 1.14
Sequence-dependent DNA structure: the role of the sugar-phosphate backbone. J Mol Biol (1998) 1.14
Roles of gamma interferon and other cytokines in suppression of the spleen cell proliferative response to concanavalin A and toxoplasma antigen during acute toxoplasmosis. Infect Immun (1995) 1.13
Identification of STAT4-dependent and independent mechanisms of resistance to Toxoplasma gondii. J Immunol (2000) 1.13
Advances in the use of genetically engineered parasites to study immunity to Toxoplasma gondii. Parasite Immunol (2008) 1.12
Anti-TGF-beta treatment promotes rapid healing of Leishmania major infection in mice by enhancing in vivo nitric oxide production. J Immunol (1999) 1.08
Identification of a role for NF-kappa B2 in the regulation of apoptosis and in maintenance of T cell-mediated immunity to Toxoplasma gondii. J Immunol (2000) 1.07
Structure and conformation of helical nucleic acids: rebuilding program (SCHNArP). J Mol Biol (1997) 1.06
Immunoregulation during toxoplasmosis. Chem Immunol (1998) 1.06
Role of CD28 in the generation of effector and memory responses required for resistance to Toxoplasma gondii. J Immunol (1999) 1.01
Enhancement of intracellular replication of Toxoplasma gondii by IL-6. Interactions with IFN-gamma and TNF-alpha. J Immunol (1994) 1.01
Molecular cloning of a cDNA encoding the human interleukin 4 receptor. Int Immunol (1990) 1.00
Temporal differences in the expression of mRNA for IL-10 and IFN-gamma in the brains and spleens of C57BL/10 mice infected with Toxoplasma gondii. Parasite Immunol (1994) 0.99
Preferential activation and expansion of human peripheral blood gamma delta T cells in response to Toxoplasma gondii in vitro and their cytokine production and cytotoxic activity against T. gondii-infected cells. J Clin Invest (1995) 0.99
Negative regulation of Th17 responses. Semin Immunol (2008) 0.99
Mouse T cell membrane proteins Rt6-1 and Rt6-2 are arginine/protein mono(ADPribosyl)transferases and share secondary structure motifs with ADP-ribosylating bacterial toxins. J Biol Chem (1996) 0.97
Targeted disruption of the bradyzoite-specific gene BAG1 does not prevent tissue cyst formation in Toxoplasma gondii. Mol Biochem Parasitol (1998) 0.97
FLK-2/FLT-3 ligand regulates the growth of early myeloid progenitors isolated from human fetal liver. Blood (1995) 0.96
Immunomodulatory role of endogenous interleukin-18 in gamma interferon-mediated resolution of replicative Legionella pneumophila lung infection. Infect Immun (2000) 0.95
Blockade of costimulation prevents infection-induced immunopathology in interleukin-10-deficient mice. Infect Immun (2000) 0.94
Gas exchange and heart rate in the harbour porpoise, Phocoena phocoena. J Comp Physiol B (2000) 0.92
A role for CD44 in the production of IFN-gamma and immunopathology during infection with Toxoplasma gondii. J Immunol (2001) 0.92
Intestinal pathology during acute toxoplasmosis is IL-4 dependent and unrelated to parasite burden. Parasite Immunol (2004) 0.91
Quantitative measurements of edge-to-face aromatic interactions by using chemical double-mutant cycles. Chemistry (2001) 0.91
Quantitative determination of intermolecular interactions with fluorinated aromatic rings. Chemistry (2001) 0.89
IL-10 is not required to prevent immune hyperactivity during memory responses to Toxoplasma gondii. Parasite Immunol (2004) 0.88
A supramolecular system for quantifying aromatic stacking interactions. Chemistry (2001) 0.87
Dichloroacetate improves cardiac efficiency after ischemia independent of changes in mitochondrial proton leak. Am J Physiol Heart Circ Physiol (2001) 0.86
Uncovered: the family relationship of a T-cell-membrane protein and bacterial toxins. Immunol Today (1996) 0.83
Chemotherapy of Trypanosoma brucei infection of the central nervous system: the use of a rapid chemotherapeutic regimen and the development of post-treatment encephalopathies. Trans R Soc Trop Med Hyg (1993) 0.83
Interleukin-10 does not contribute to the pathogenesis of a virulent strain of Toxoplasma gondii. Parasite Immunol (2001) 0.83
Patients infected with Leishmania donovani chagasi can have antibodies that recognize heat shock and acidic ribosomal proteins of Trypanosoma cruzi. Mol Biochem Parasitol (1991) 0.82
The role of the polyamine inhibitor eflornithine in the neuropathogenesis of experimental murine African trypanosomiasis. Neuropathol Appl Neurobiol (1997) 0.81
Presence of delta-sleep-inducing peptide-like material in human milk. J Clin Endocrinol Metab (1984) 0.79
Detection of volatile organic compounds using porphyrin derivatives. J Phys Chem B (2010) 0.79
Alkylamine sensing using langmuir-blodgett films of n-alkyl-N-phenylamide-substituted zinc porphyrins. J Phys Chem B (2008) 0.79
Altered endochondral ossification in collagen X mouse models leads to impaired immune responses. Dev Dyn (2008) 0.78
Sequence-structure relationships in DNA oligomers: a computational approach. J Am Chem Soc (2001) 0.78
Immunity to Toxoplasma gondii--into the 21st century. Parasite Immunol (2015) 0.77
Self-assembly of oligomeric porphyrin rings. Org Lett (2000) 0.77
Similarity in variable antigen type composition of Trypanosoma brucei rhodesiense populations in different sites within the mouse host. Trans R Soc Trop Med Hyg (1986) 0.77
Treatment with interleukin 12 in combination with atovaquone or clindamycin significantly increases survival of mice with acute toxoplasmosis. Antimicrob Agents Chemother (1997) 0.76
Passive stretch relationships in human uterine muscle. Am J Obstet Gynecol (1966) 0.76
Immune deficiencies and parasitic diseases. Parasite Immunol (2006) 0.75
Evaluation of murine interleukin 4 (IL-4) receptor expression using anti-receptor monoclonal antibodies and S1 nuclease protection analyses. Cell Immunol (1991) 0.75
Toxoplasma gondii induces changes in intracellular calcium in macrophages. Parasitology (2007) 0.75
Current status of the first postdoctoral year. Present concepts from American surgical boards: obstetrics and gynecology. Bull Am Coll Surg (1975) 0.75
Exploiting the cell membrane for the production of heterologous proteins in Escherichia coli. Biotechnol Appl Biochem (1990) 0.75
Dysfunction of the forces of labor. Clin Anesth (1965) 0.75
Intrauterine fetal transfusion for severe Rh disease. Northwest Med (1968) 0.75
Aluminum phthalocyanine-streptavidin: new, sensitive fluorescent tracer for immunoassay. Clin Chem (1991) 0.75
The role of natural killer cells in innate resistance to infection. J Immunol (1997) 0.75
Obstetrical management of the Rh negative patient. S D J Med (1965) 0.75
Continuum of medical education in obstetrics and gynecology. J Med Educ (1980) 0.75
Biodegradable microspheres: polyacryl starch microparticles as a delivery system for the antileishmanial drug, sodium stibogluconate. J Pharm Pharmacol (1987) 0.75
Cytoplasmic and periplasmic expression of a highly basic protein, human interleukin 4, in Escherichia coli. J Ind Microbiol (1990) 0.75
Effects of intra-amniotic injection of hypertonic saline on uterine activity, blood and amniotic fluid volumes, and electrolyte concentrations. Am J Obstet Gynecol (1968) 0.75
The goal of learning--to be enlightened. Presidential address. Am J Obstet Gynecol (1976) 0.75
Effect of pudendal, spinal, and peridural block anesthesia on the second stage of labor. Am J Obstet Gynecol (1972) 0.75
Methodology and evaluation of undergraduate curriculum in obstetrics and gynecology. Am J Obstet Gynecol (1969) 0.75
Comparison of spontaneous, oxytocin-stimulated, and hypertonic saline-induced labor by different methods of record analysis. Am J Obstet Gynecol (1970) 0.75